Pulmonary Embolism in Women Using Estrogen‑Containing Oral Contraceptives – Guideline‑Based Facts

Diagnostic Assessment

Dyspnea combined with tachypnea (respiratory rate > 20 /min) is present in ~90 % of acute PE cases; only ~3 % of cases lack dyspnea, tachypnea, and pleuritic chest pain. – British Thoracic Society (BTS) guideline, 1997. 1
Tachycardia, anxiety, cough, hemoptysis, and leg pain/clinical DVT are additional supportive features, but no single sign reliably predicts PE on its own. – BTS guideline, 1997. 2
Structured clinical decision rules (Wells or Geneva scores) should be employed rather than reliance on isolated clinical findings, because individual signs have poor predictive value. – BTS guideline, 1997. 1
Electrocardiography and chest radiography are mandatory first‑line investigations to exclude alternative diagnoses that can mimic PE (e.g., myocardial infarction, heart failure, pneumothorax, pneumonia). – BTS guideline, 1997. 1
Arterial blood‑gas analysis is recommended to quantify hypoxia and calculate the alveolar‑arterial gradient, aiding in the assessment of severity. – BTS guideline, 1997. 1
In the 1997 BTS era, pulmonary angiography was the gold‑standard imaging test; contemporary practice now uses CT pulmonary angiography (CTPA) as the standard for hemodynamically stable patients with high clinical probability. – BTS guideline, 1997. 1

Therapeutic anticoagulation should be started as soon as PE is confirmed, and may be initiated on the basis of high clinical suspicion when no contraindications exist. – BTS guideline, 1997. [1][2]
Low‑molecular‑weight heparin (LMWH) is the preferred initial agent because it requires no routine laboratory monitoring and is easy to administer. – BTS guideline, 1997. 2
Unfractionated heparin is advised when rapid reversibility is needed (e.g., renal impairment or high bleeding risk). – BTS guideline, 1997. 2
If clinical suspicion is high and there are no contraindications, anticoagulation must not be delayed while awaiting definitive imaging. – BTS guideline, 1997. 1

Recurrent PE‑related mortality is low after anticoagulation; the PIOPED study reported a 25 % one‑year mortality among anticoagulated PE patients, but deaths were overwhelmingly due to underlying comorbidities rather than recurrent embolism. – BTS guideline, 1997. 1
Young, otherwise healthy women on estrogen‑containing oral contraceptives have an excellent prognosis after appropriate treatment. – BTS guideline, 1997. 1

For provoked VTE (i.e., oral‑contraceptive‑associated PE), a standard anticoagulation course of 3–6 months is recommended. – BTS guideline, 1997. 1
Screening for inherited thrombophilia (e.g., Factor V Leiden, prothrombin mutation) should be considered at follow‑up in patients without other apparent risk factors, especially when any of the following apply:

Deep vein thrombosis (DVT) is more likely to occur than pulmonary embolism (PE) in patients using estrogen-containing contraceptives, as DVT typically precedes PE in the pathophysiological progression of venous thromboembolism (VTE) 3, 4

Combined oral contraceptives (containing both estrogen and progestogen) increase VTE risk approximately two- to six-fold over baseline 3
Contraceptive use is the most frequent VTE risk factor in women of reproductive age 3
The absolute risk of VTE remains relatively low in most of the combined oral contraceptive users worldwide 3

PE is usually associated with DVT and is rarely unprovoked 3
PE occurs when a thrombus (blood clot) that forms in the deep veins (DVT), typically in the legs, breaks off and travels to the pulmonary arteries 5
PE interferes with both circulation and gas exchange, with right ventricular failure due to acute pressure overload being the primary cause of death in severe PE 5

Third-generation combined oral contraceptives (containing progestogens like desogestrel or gestodene) are associated with higher VTE risk than second-generation contraceptives (containing progestogens like levonorgestrel or norgestrel) 3
Severe inherited thrombophilia significantly increases the risk of VTE in women using estrogen contraceptives 3, 6

Hormone-releasing intrauterine devices and some progesterone-only pills (used at contraceptive doses) are not associated with a significant increase in VTE risk 3, 6
These safer alternatives are often recommended for women with a personal or strong family history of VTE 3

Women who develop hormone-associated VTE are generally advised to discontinue oral contraceptive use 6